Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges

키워드

참고문헌 (105)

1. Cooperberg MR, "The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE)", J Urol, 171, pp.1393~1401 (2004), a national disease registry
2. Cooperberg MR, "Contemporary trends in low risk prostate cancer: risk assessment and treatment", J Urol, 178, pp.14~19 (2007)
3. Oesterling JE, "Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy", J Urol, 139, pp.766~772 (1988)
4. Partin AW, "The clinical usefulness of prostate specific antigen: update 1994", J Urol, 152, pp.1358~1368 (1994)
5. Presti JC Jr, "Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy", Urology, 52, pp.1079~1084 (1988)
6. Pound CR, "Natural history of progression after PSA elevation following radical prostatectomy", JAMA, 281, pp.1591~1597 (1999)
7. Freedland SJ, "Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score", J Urol, 168, pp.110~115 (2002)
8. Moul JW, "Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases", J Urol, 166, pp.1322~1327 (2001)
9. Hull GW, "Cancer control with radical prostatectomy alone in 1,000 consecutive patients", J Urol, 167, pp.528~534 (2002)
10. Amling CL, "Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?", J Urol, 165, pp.1146~1151 (2001)
11. Iselin CE, "Radical perineal prostatectomy: oncological outcome during a 20-year period", J Urol, 161, pp.163~168 (1999)
12. Freedland SJ, "Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen", Urology, 61, pp.365~369 (2003)
13. Cookson MS, "Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes", J Urol, 177, pp.540~545 (2007)
14. Heidenreich A, "EAU guidelines on prostate cancer", Eur Urol, 53, pp.68~80 (2008)
15. Boccon-Gibod L, "Management of prostate-specific antigen relapse in prostate cancer: a European Consensus", Int J Clin Pract, 58, pp.382~390 (2004)
16. Stephenson AJ, "Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition", J Clin Oncol, 24, pp.3973~3978 (2006)
17. Scher HI, "Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group", J Clin Oncol, 22, pp.537~556 (2004)
18. Ellis WJ, "Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay", Urology, 50, pp.573~579 (1997)
19. Doherty AP, "Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival", Br J Cancer, 83, pp.1432~1436 (2000)
20. Ornstein DK, "Evaluation and management of the man who has failed primary curative therapy for prostate cancer", Urol Clin North Am, 25, pp.591~601 (1998)
21. Diamandis EP, "Nonprostatic sources of prostate-specific antigen", Urol Clin North Am, 24, pp.275~282 (1997)
22. Karakiewicz PI, "Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5,831 patients", Urology, 66, pp.1245~1250 (2005)
23. Khan MA, "Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer", Urology, 62, pp.866~871 (2003)
24. Thompson IM, "Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial", J Urol, 181, pp.956~962 (2009)
25. Swanson GP, "Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794", J Clin Oncol, 25, pp.2225~2229 (2007)
26. Bolla M, "Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)", Lancet, 366, pp.572~578 (2005)
27. Wiegel T, "Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02", AUO AP 09, J Clin Oncol, pp.2009, 27[DOI]
28. Cher ML, "Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy", J Urol, 160, pp.1387~1391 (1998)
29. Dotan ZA, "Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy", J Clin Oncol, 23, pp.1962~1968 (2005)
30. Gomez P, "Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?", BJU Int, 94, pp.299~302 (2004)
31. Okotie OT, "Predictors of metastatic disease in men with biochemical failure following radical prostatectomy", J Urol, 171, pp.2260~2264 (2004)
32. Kane CJ, "Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy", Urology, 61, pp.607~611 (2003)
33. Saleem MD, "Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy", Urology, 51, pp.283~286 (1998)
34. Connolly JA, "Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins", Urology, 47, pp.225~231 (1996)
35. Shekarriz B, "Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage", Urology, 54, pp.1044~1048 (1999)
36. Scattoni V, "Diagnosis of local recurrence after radical prostatectomy", BJU Int, 93, pp.680~688 (2004)
37. Naya Y, "Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy", Urology, 66, pp.350~355 (2005)
38. Deliveliotis C, "Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy", World J Urol, 25, pp.309~313 (2007)
39. Koppie TM, "Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?", J Urol, 166, pp.111~115 (2001)
40. Sella T, "Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging", Radiology, 231, pp.379~385 (2004)
41. Miralbell R, "Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure", Int J Radiat Oncol Biol Phys, 67, pp.356~361 (2007)
42. Sciarra A, "Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer", Eur Urol, 54, pp.589~600 (2008)
43. Hinkle GH, "Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide", Cancer, 83, pp.739~747 (1998)
44. Raj GV, "Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy", Cancer, 94, pp.987~996 (2002)
45. Petronis JD, "Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer", Clin Nucl Med, 23, pp.672~677 (1998)
46. Elgamal AA, "ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients", Prostate, 37, pp.261~269 (1998)
47. Nagda SN, "Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer", Int J Radiat Oncol Biol Phys, 67, pp.834~840 (2007)
48. Koontz BF, "Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer", Int J Radiat Oncol Biol Phys, 71, pp.358~361 (2008)
49. Thomas CT, "Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy", J Clin Oncol, 21, pp.1715~1721 (2003)
50. choline PET, "CT in prostate cancer patients with biochemical recurrence after radical prostatectomy", World J Urol, 27, pp.619~625 (2009)
51. Castellucci P, "Influence of trigger PSA and PSA kinetics on 11C-Choline PET", CT detection rate in patients with biochemical relapse after radical prostatectomy, 2009, pp.50, 1394~1400
52. choline PET, "CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvicretroperitoneal lymphadenectomy", Eur Urol, 52, pp.423~429 (2007)
53. Schilling D, "Histological verification of 11C-choline-positron emission", computed tomographypositive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer, 2008, pp.102, 446~451
54. Vees H, "18F-choline and", or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng, BJU Int, pp.2007, 99[DOI]
55. Freedland SJ, "Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy", JAMA, 294, pp.433~439 (2005)
56. "J Urol", 2004, 1141~1147
57. "Int J Radiat Oncol Biol Phys", 2006, 1162~1167
58. Trock BJ, "Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy", JAMA, 299, pp.2760~2769 (2008)
59. Boorjian SA, "Radiation therapy after radical prostatectomy: impact on metastasis and survival", J Urol, 182, pp.2708~2714 (2009)
60. Choo R, "(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy", Int J Radiat Oncol Biol Phys, 53, pp.269~276 (2002)
61. "J Clin Oncol", 2007, 2035~2041
62. Choo R, "Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery", Radiother Oncol, 74, pp.163~167 (2005)
63. Macdonald OK, "Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy", Int J Radiat Oncol Biol Phys, 58, pp.1530~1535 (2004)
64. Ray GR, "External beam radiation salvage for residual or recurrent local tumor following radical prostatectomy", J Urol, 132, pp.926~930 (1984)
65. Rosen EM, "Radiotherapy for localized prostate carcinoma", Int J Radiat Oncol Biol Phys, 10, pp.2201~2210 (1984)
66. Loeb S, "Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy", Eur Urol, 54, pp.88~94 (2008)
67. De Meerleer G, "Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy", Radiother Oncol, 89, pp.205~213 (2008)
68. Buskirk SJ, "Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system", J Urol, 176, pp.985~990 (2006)
69. Pisansky TM, "Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer", J Urol, 163, pp.845~850 (2000)
70. Neuhof D, "Longterm results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy", Int J Radiat Oncol Biol Phys, 67, pp.1411~1417 (2007)
71. Wiegel T, "Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study", Int J Radiat Oncol Biol Phys, 73, pp.1009~1016 (2009)
72. "J Clin Oncol", 2001, 1030~1039
73. Pazona JF, "Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates", J Urol, 174, pp.1282~1286 (2005)
74. Stephenson AJ, "Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy", JAMA, 291, pp.1325~1332 (2004)
75. Maier J, "Salvage radiation for a rising PSA following radical prostatectomy", Urologic Oncology, 22, pp.50~56 (2004)
76. King CR, "Improved outcomes with higher doses for salvage radiotherapy after prostatectomy", Int J Radiat Oncol Biol Phys, 71, pp.23~27 (2008)
77. Moreira DM, "Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database", BJU Int, 104, pp.1452~1456 (2009)
78. MacDonald OK, "Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?", Urology, 64, pp.760~764 (2004)
79. Song DY, "Salvage radiotherapy for rising or persistent PSA after radical prostatectomy", Urology, 60, pp.281~287 (2002)
80. Macdonald OK, "Ferrigni RG, Novicki DE, et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy", J Urol, 170, pp.1833~1837 (2003)
81. Catton C, "Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate", Radiother Oncol, 59, pp.51~60 (2001)
82. Quero L, "Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience", BMC Cancer, ~ (2008)
83. Sasaki T, "Low preradiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer", Anticancer Res, 26, pp.2367~2374 (2006)
84. Symon Z, "Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models", Am J Clin Oncol, 29, pp.446~450 (2006)
85. King CR, "Radiotherapy after prostatectomy: is the evidence for dose escalation out there?", Int J Radiat Oncol Biol Phys, 71, pp.346~350 (2008)
86. Bernard JR Jr, "Salvage Radiotherapy for Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer: Dose-Response Analysis", Int J Radiat Oncol Biol Phys, 76, pp.735~740 (2010)
87. Feng M, "Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy", Int J Radiat Oncol Biol Phys, 68, pp.1417~1423 (2007)
88. Peterson JL, "Late toxicity after postprostatectomy salvage radiation therapy", Radiother Oncol, 93, pp.203~206 (2009)
89. Pearse M, "Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy", Int J Radiat Oncol Biol Phys, 72, pp.792~798 (2008)
90. Choo R, "Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse", Int J Radiat Oncol Biol Phys, 75, pp.983~989 (2009)
91. Katz MS, "Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer", J Clin Oncol, 21, pp.483~489 (2003)
92. Tiguert R, "Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level", J Urol, 170, pp.447~450 (2003)
93. King CR, "Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?", Int J Radiat Oncol Biol Phys, 59, pp.341~347 (2004)
94. Taylor N, "Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer", Int J Radiat Oncol Biol Phys, 56, pp.755~763 (2003)
95. Yokomizo A, "Randomized controlled trial to evaluate radiotherapy +", - endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401, 2005, pp.35, 34~36
96. Ward JF, "Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy", J Urol, 172, pp.2244~2248 (2004)
97. Brooks JP, "Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors", J Urol, 174, pp.2204~2208 (2005)
98. Anscher MS, "Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years", Int J Radiat Oncol Biol Phys, 48, pp.369~375 (2000)
99. Peyromaure M, "Salvage radiotherapy for biochemical recurrence after radical prostatectomy: a study of 62 patients", Urology, 62, pp.503~507 (2003)
100. Chawla AK, "Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors", Urology, 59, pp.726~731 (2002)
101. De la Taille A, "Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy", BJU Int, 90, pp.887~892 (2002)
102. Liauw SL, "Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience", Urology, 61, pp.1204~1210 (2003)
103. Tomita N, "Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy", J Cancer Res Clin Oncol, 135, pp.1561~1567 (2009)
104. Delongchamps NB, "Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence", Can J Urol, 16, pp.4813~4819 (2009)
105. Jacinto AA, "Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy", Radiat Oncol, 2, pp.8~ (2007)

관련 논문AI추천